HK1193405A1 - 適用於治療哺乳動物異常細胞生長的 甲基-氨甲酰基 苯基硫基 吡啶- -基 乙烯基 吲唑的晶型 - Google Patents

適用於治療哺乳動物異常細胞生長的 甲基-氨甲酰基 苯基硫基 吡啶- -基 乙烯基 吲唑的晶型

Info

Publication number
HK1193405A1
HK1193405A1 HK14106750.1A HK14106750A HK1193405A1 HK 1193405 A1 HK1193405 A1 HK 1193405A1 HK 14106750 A HK14106750 A HK 14106750A HK 1193405 A1 HK1193405 A1 HK 1193405A1
Authority
HK
Hong Kong
Prior art keywords
phenylsulfanyl
methylcarbamoyl
indazole
ethenyl
pyridin
Prior art date
Application number
HK14106750.1A
Other languages
English (en)
Inventor
．坎佩塔
．柴卡爾
．麥克勞林
．辛格
Original Assignee
輝瑞產品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39831473&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1193405(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 輝瑞產品公司 filed Critical 輝瑞產品公司
Publication of HK1193405A1 publication Critical patent/HK1193405A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
HK14106750.1A 2007-04-05 2010-06-09 適用於治療哺乳動物異常細胞生長的 甲基-氨甲酰基 苯基硫基 吡啶- -基 乙烯基 吲唑的晶型 HK1193405A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91037907P 2007-04-05 2007-04-05
US97654607P 2007-10-01 2007-10-01
US3155408P 2008-02-26 2008-02-26

Publications (1)

Publication Number Publication Date
HK1193405A1 true HK1193405A1 (zh) 2014-09-19

Family

ID=39831473

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14106750.1A HK1193405A1 (zh) 2007-04-05 2010-06-09 適用於治療哺乳動物異常細胞生長的 甲基-氨甲酰基 苯基硫基 吡啶- -基 乙烯基 吲唑的晶型

Country Status (23)

Country Link
US (1) US8791140B2 (zh)
EP (4) EP2134702B2 (zh)
JP (2) JP5869197B2 (zh)
KR (1) KR101237588B1 (zh)
CN (2) CN101679356A (zh)
AR (1) AR065931A1 (zh)
AU (1) AU2008236444B2 (zh)
BR (1) BRPI0809471A2 (zh)
CA (1) CA2682859C (zh)
CY (1) CY1119119T1 (zh)
DK (1) DK2134702T4 (zh)
ES (2) ES2634866T5 (zh)
FI (1) FI2134702T4 (zh)
HK (1) HK1193405A1 (zh)
IL (1) IL201320A (zh)
MX (1) MX2009010761A (zh)
NZ (1) NZ580126A (zh)
PL (1) PL2134702T5 (zh)
PT (1) PT2134702T (zh)
RU (1) RU2518898C2 (zh)
SI (1) SI2134702T2 (zh)
TW (1) TWI481602B (zh)
WO (1) WO2008122858A2 (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI2134702T4 (fi) * 2007-04-05 2023-09-12 6-[2-(metyylikarbamoyyli)fenyylisulfanyyli]-3-E-[2-(pyridiini-2-yyli)etenyyli]indatsolin kidemuotoja jotka soveltuvat nisäkkäiden poikkeavan solukasvun hoitamiseen
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
JO3062B1 (ar) * 2010-10-05 2017-03-15 Lilly Co Eli R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
TW201328725A (zh) 2011-09-30 2013-07-16 Pfizer Ｎ－甲基－２－［３－（（ｅ）－２－吡啶－２－基－乙烯基）－１ｈ－吲唑－６－基硫烷基］苯甲醯胺之藥學組成物
WO2013068909A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia
US10098859B2 (en) 2012-09-05 2018-10-16 Amri Ssci, Llc Cocrystals of p-coumaric acid
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CN104230886A (zh) * 2013-06-24 2014-12-24 南京华威医药科技开发有限公司 阿昔替尼新晶型
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
CN104650034A (zh) * 2013-11-22 2015-05-27 天津市汉康医药生物技术有限公司 一种稳定的阿西替尼化合物
CA2937521C (en) 2014-02-04 2023-08-29 Pfizer, Inc. Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
JP6407257B2 (ja) * 2014-03-31 2018-10-17 千寿製薬株式会社 アルキニルインダゾール誘導体及びその用途
WO2016032927A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
US10800846B2 (en) 2015-02-26 2020-10-13 Merck Patent Gmbh PD-1/PD-L1 inhibitors for the treatment of cancer
WO2016178150A1 (en) * 2015-05-05 2016-11-10 Shilpa Medicare Limited Novel polymorphs of axitinib
CA2989586A1 (en) 2015-06-16 2016-12-22 Pfizer, Inc. Pd-l1 antagonist combination treatments
CA3025049A1 (en) * 2016-05-16 2017-11-23 Pulmagen Therapeutics (Asthma) Limited Crystal of quinoline derivative
IL265762B2 (en) 2016-10-06 2024-04-01 Merck Patent Gmbh Dosing regimen of avolumab for cancer treatment
CN106883212A (zh) * 2017-03-16 2017-06-23 合肥拓锐生物科技有限公司 一种xli晶型阿昔替尼的制备方法
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
JP2022532540A (ja) 2019-05-09 2022-07-15 シントン・ビー．ブイ． アキシチニブを含有する医薬組成物
CN111187253B (zh) * 2020-01-09 2023-05-09 鲁南制药集团股份有限公司 一种阿昔替尼新晶型
CN115461040A (zh) 2020-03-25 2022-12-09 视觉治疗股份有限公司 含有酪氨酸激酶抑制剂的眼用植入物
WO2022000265A1 (zh) * 2020-06-30 2022-01-06 天津理工大学 一种阿西替尼与戊二酸共晶及其制备方法
CN113943270B (zh) * 2020-07-15 2023-05-09 鲁南制药集团股份有限公司 一种阿昔替尼晶型
CN113943271B (zh) * 2020-07-15 2023-11-14 鲁南制药集团股份有限公司 一种阿昔替尼晶型及其制备方法
CN114685437B (zh) * 2020-12-25 2022-12-09 鲁南制药集团股份有限公司 阿昔替尼与糖精共晶
CN114685436B (zh) * 2020-12-25 2022-12-02 鲁南制药集团股份有限公司 阿昔替尼糖精共晶水合物
CN114685431B (zh) * 2020-12-26 2022-11-29 鲁南制药集团股份有限公司 一种阿昔替尼柠檬酸盐晶型
CN114685434B (zh) * 2020-12-28 2023-06-16 鲁南制药集团股份有限公司 一种阿昔替尼与戊二酸共晶
CN114685433B (zh) * 2020-12-28 2022-11-25 鲁南制药集团股份有限公司 一种阿昔替尼香草酸共晶盐及其制备
CN114685432B (zh) * 2020-12-28 2022-11-25 鲁南制药集团股份有限公司 阿昔替尼盐晶型及其制备方法
CN114685435B (zh) * 2020-12-28 2023-01-31 鲁南制药集团股份有限公司 阿昔替尼马来酸盐晶型及其制备
US20240117030A1 (en) 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
EP4282415A1 (en) 2022-05-26 2023-11-29 Genepharm S.A. A stable tablet composition of axitinib

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
CZ20022332A3 (cs) † 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
RU2341263C2 (ru) 2003-04-03 2008-12-20 Пфайзер Инк. Лекарственные формы, содержащие ag013736
CN101044138A (zh) 2004-11-02 2007-09-26 辉瑞有限公司 吲唑化合物的制备方法
RU2007116107A (ru) * 2004-11-02 2008-11-10 Пфайзер Инк. (US) Способы получения индазольных соединений
CN101094836A (zh) 2004-11-02 2007-12-26 辉瑞大药厂 制备吲唑化合物的方法
WO2006048751A1 (en) † 2004-11-02 2006-05-11 Pfizer Inc. Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole
CN101052633A (zh) 2004-11-02 2007-10-10 辉瑞大药厂 制备吲唑化合物的方法
EP1885338A1 (en) 2005-05-19 2008-02-13 Pfizer, Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
FI2134702T4 (fi) 2007-04-05 2023-09-12 6-[2-(metyylikarbamoyyli)fenyylisulfanyyli]-3-E-[2-(pyridiini-2-yyli)etenyyli]indatsolin kidemuotoja jotka soveltuvat nisäkkäiden poikkeavan solukasvun hoitamiseen
TW201328725A (zh) † 2011-09-30 2013-07-16 Pfizer Ｎ－甲基－２－［３－（（ｅ）－２－吡啶－２－基－乙烯基）－１ｈ－吲唑－６－基硫烷基］苯甲醯胺之藥學組成物

Also Published As

Publication number Publication date
TW200911781A (en) 2009-03-16
MX2009010761A (es) 2009-10-28
BRPI0809471A2 (pt) 2014-09-09
IL201320A0 (en) 2010-05-31
ES2634866T3 (es) 2017-09-29
TWI481602B (zh) 2015-04-21
EP3252047B1 (en) 2022-05-11
NZ580126A (en) 2012-03-30
JP2014193900A (ja) 2014-10-09
RU2009136593A (ru) 2011-04-10
PL2134702T3 (pl) 2017-10-31
US8791140B2 (en) 2014-07-29
WO2008122858A9 (en) 2009-06-18
AU2008236444A1 (en) 2008-10-16
CN103626739A (zh) 2014-03-12
EP2134702B1 (en) 2017-05-31
IL201320A (en) 2016-05-31
EP2134702A2 (en) 2009-12-23
JP2009019030A (ja) 2009-01-29
WO2008122858A2 (en) 2008-10-16
SI2134702T2 (sl) 2023-12-29
US20100179329A1 (en) 2010-07-15
EP3252047A3 (en) 2018-08-15
JP5869197B2 (ja) 2016-02-24
KR101237588B1 (ko) 2013-02-27
EP3252047A2 (en) 2017-12-06
WO2008122858A8 (en) 2009-11-26
DK2134702T3 (en) 2017-08-21
EP4249063A3 (en) 2024-03-13
AR065931A1 (es) 2009-07-08
RU2518898C2 (ru) 2014-06-10
CN103626739B (zh) 2015-12-30
KR20090127949A (ko) 2009-12-14
ES2919351T3 (es) 2022-07-26
EP4249063A2 (en) 2023-09-27
EP2134702B2 (en) 2023-08-30
CA2682859C (en) 2013-10-08
AU2008236444B2 (en) 2012-06-28
DK2134702T4 (da) 2023-09-25
WO2008122858A3 (en) 2009-05-07
FI2134702T4 (fi) 2023-09-12
PT2134702T (pt) 2017-07-31
CY1119119T1 (el) 2018-02-14
EP4074702A1 (en) 2022-10-19
ES2634866T5 (es) 2024-03-04
PL2134702T5 (pl) 2023-12-04
CN101679356A (zh) 2010-03-24
CA2682859A1 (en) 2008-10-16
SI2134702T1 (sl) 2017-07-31

Similar Documents

Publication Publication Date Title
HK1193405A1 (zh) 適用於治療哺乳動物異常細胞生長的 甲基-氨甲酰基 苯基硫基 吡啶- -基 乙烯基 吲唑的晶型
TWI369205B (en) Sulfonyl amide derivatives for the treatment of abnormal cell growth
ZA200804488B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
EP2343362B8 (en) Improved process for the culturing of cells
HUE042044T2 (hu) Elektroporációs készülékek sejtek elektroporációjára emlõsökben
IL211176A0 (en) Methods for the production of ips cells
IL209740A0 (en) Methods for the production of ips cells using non-viral approach
ZA201005208B (en) Process for the manufacture of solar cells
AP2006003790A0 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
IL216084A0 (en) 2,4-diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation
SI2173891T1 (sl) Encimski proces za pridobivanje korteksolon-17-alfa-propionata v kristaliniäśni obliki iii
EP2154242A4 (en) METHOD FOR INDUCING MYOCARDIAL CELL DIFFERENTIATION USING G-CSF
EP2206745A4 (en) By means of active energy radiation, heat-treatable composition and method for the production thereof
WO2010083240A9 (en) Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds
GB0814443D0 (en) Process for cultivating cells
ZA200906990B (en) Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals
AU2008900382A0 (en) Method for treating B cell disorders
IL244553A0 (en) Altered placental cells
AU2007900771A0 (en) Method and Apparatus for the Treatment of Abnormal Cell Structures
HUP0700350A2 (en) Process for increasing the number of stem cells in the blood circulation
IL192452A (en) A process for producing titanium salts
PL389357A1 (pl) Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
GB0812609D0 (en) Process for the preparation of deoxynojirimycin
PL389673A1 (pl) Nowe pochodne 1-(2-pirydylo)-6-podstawione imidazo [1, 2-a][1, 3, 5] triazyny oraz sposób ich wytwarzania